Observational Study of Obstructive Lung Disease NOVELTY
Research payments
$1,389,703
Through program year 2024, $1,389,703 in research payments was reported against Observational Study of Obstructive Lung Disease NOVELTY, across 163 payments, paid by AstraZeneca UK Limited.
- Paid by
- AstraZeneca UK Limited
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $57,136 | 5 |
| 2023 | Research | $41,274 | 11 |
| 2022 | Research | $61,652 | 25 |
| 2021 | Research | $271,248 | 43 |
| 2020 | Research | $488,418 | 38 |
| 2019 | Research | $469,977 | 41 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Ellen Epstein Rockville Centre, NY Named on 3 payments
- Daniel Sousa Fall River, MA Named on 3 payments
- Richard Wachs Albuquerque, NM Named on 3 payments
- Fernando Holguin Aurora, CO Named on 3 payments
- Mitzie Hewitt Buckley, MI Named on 3 payments
- Ari Klapholz New York, NY Named on 3 payments
- Peruvemba Sriram Gainesville, FL Named on 3 payments
- Bradley Chipps Sacramento, CA Named on 3 payments
- Alain Eid Colorado Springs, CO Named on 3 payments
- Loay Al Asadi Charleston, WV Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.